ArcticZymes Technologies Reports Strong Q4 and FY 2025. Accelerating Sales Growth and Improved Profitability

ArcticZymes returned to growth in 2025 with Q4 total revenue of NOK 34.7m (+31% YoY) and sales revenue of NOK 34.1m (+39% YoY), driving Q4 EBITDA to NOK 8.3m (margin 24% vs 11% a year ago). Full-year 2025 revenue reached NOK 118.2m (+9%) with sales of NOK 112.6m (+8%) and EBITDA of NOK 12.0m (2024: NOK 5.1m); the firm ended with NOK 187.8m cash, NOK 76.9m in liquid interest-bearing funds, no interest-bearing debt and positive net cash flow. Segment strength included Biomanufacturing (Q4 NOK 15.2m, +25%; GMP-grade sales +106% YoY) and Molecular Tools (Q4 NOK 18.9m, +55%), and management highlights continued commercial momentum, a planned RNA enzyme portfolio build (ET-N1) and disciplined cost management supporting further organic growth.

Analysis

Market structure: ArcticZymes (OSE:AZT) is showing a sharp inflection — Q4 sales +39% YoY and Q4 EBITDA margin 24% — driven by GMP biomanufacturing (GMP sales +106% in Q4). Winners include CDMOs and suppliers of GMP enzymes and RNA tool providers; losers are generic reagent suppliers that lack GMP capabilities. Cash NOK 264.7m (cash + liquid funds) vs NOK 118m revenue gives AZT >2x revenue runway, reducing immediate financing risk and supporting continued commercial scaling; modest FX sensitivity if USD/NOK moves >3% quarterly.

Risk assessment: Main tail risks are customer concentration (a few CDMO/key accounts) where loss of one large buyer could cut revenue 15–30% (estimate) and regulatory/GMP compliance failures that could halt shipments for months. Immediate (days) risks: investor reaction to the webcast and Q1 order cadence; short-term (weeks–months): visibility on recurring GMP orders and ET-N1 launch timing; long-term: IP disputes or failure to convert CDMO pilots to commercial contracts. Hidden dependency: Molecular Tools reliance on a single key account creates revenue lumpiness and forecasting error.

Trade implications: Direct play — establish a modest 2–3% long position in AZT ahead of Q1 2026 (12-month target +40–60%) while keeping a 20% stop-loss; if options are available, prefer a 9‑month call spread (buy 0–25% OTM, sell 50% OTM) to cap premium. Relative value — pair trade long AZT vs short XBI (SPDR S&P Biotech ETF) to isolate company-specific GMP acceleration vs sector cyclicality over 6–12 months. Rebalance if GMP sales growth fails to exceed +30% QoQ for two consecutive quarters or if cash burn accelerates.

Contrarian angles: Consensus may underweight AZT because FY growth was only +9% despite strong Q4; market is likely missing the secular shift to GMP enzyme demand in biomanufacturing and the optionality from ET-N1 and metagenomics. The cash-rich balance sheet creates an acquisition or capacity-expansion option that could re-rate the stock; contrarian downside is capped by cash buffer but upside depends on converting CDMO pilots into multi-year contracts. Historical parallel: small enzyme suppliers that captured GMP CDMO pipelines often re-rated 2–3x after 2–4 quarters of repeat orders; failure to convert would, conversely, lead to a swift derating.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ArcticZymes (OSE:AZT) within 2 weeks, target +40–60% upside in 12 months; set a hard stop-loss at −20% and review after Q1 2026 results or webcast updates.
• Implement a pair trade: long AZT vs short equal-dollar XBI (SPDR S&P Biotech ETF) for 6–12 months to isolate company-specific GMP momentum; close positions if AZT GMP revenue growth <+30% QoQ for two consecutive quarters.
• If liquid options exist, buy a 9‑month AZT call spread (buy ~25% OTM, sell ~50% OTM) sized to represent 1–2% portfolio exposure, or alternatively buy 6‑month 15% OTM puts as downside protection when holding the stock.
• Monitor three near-term catalysts within 30–90 days: (1) Q1 order cadence and repeat GMP bookings, (2) ET-N1 launch commercial timetable, and (3) any customer-concentration disclosures; trim position by 50% if any single customer is revealed to account for >25% revenue or if cash burn exceeds NOK 10m per quarter.